Elevated pulmonary vascular resistance is associated with acute exacerbation admission in patients with chronic obstructive pulmonary disease-related pulmonary hypertension
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Background and objective Pulmonary hypertension (PH) is defined by elevated mean pulmonary arterial pressure (mPAP), and elevated pulmonary vascular resistance (PVR) reflects pulmonary vascular abnormalities. The clinical significance of severe PH in patients with chronic obstructive pulmonary disease (COPD) has not been fully elucidated. We aimed to investigate the predictive value of PVR for acute exacerbation (AE ) admission in patients with COPD-related PH (COPD-PH). Methods We retrospectively analysed COPD patients who underwent right heart catheterization (RHC) for the initial evaluation of PH from January 2019 to January 2023. These patients were classified into groups with or without PH, and further into non-severe or severe PH based on PVR. The clinical significance of PVR in predicting AE admission was analyzed. Results Among 2729 patients, 268 underwent RHC, and the clinical datas of 99 patients were included in the final analysis. 76 (76.8%) patients were readmitted due to acute exacerbation within one year. In Cox proportional hazards analyses with adjustment for covariates, severe PH patients had a higher risk of AE admission( (HR 5.478, 95%CI 2.471 to 12.114, P =0.000; HR 7.097, 95%CI 2.994 to 16.825, P =0.000; HR 8.210, 95%CI 3.457 to 19.497, P =0.000, respectively). Severe PH was associated with poorer AE admission rates (log-rank χ 2 =19.4; P< 0.0001). Conclusions Elevated PVR serves as an independent predictor for acute exacerbation-related hospitalization in patients with COPD-PH: Specifically, a PVR >5 Wood units (defining severe PH) is independently associated with a significantly increased risk of admission due to AE. Trial registration The registration number(rhBNP-PH2022); Date of registration(June 30, 2022)(retrospectively registered).
Fields of Study & Subjects
Pulmonary Hypertension Research and Treatments
Chronic Obstructive Pulmonary Disease (COPD) Research
Transplantation: Methods and Outcomes
Publication details
- Journal / source
- Respiratory Medicine
- Volume
- 256
- Pages
- 108801–108801
- Publication date
- 31 March 2026
- Language
- EN